Biotech Showcase Sessions
With the support of the Alzheimer's Drug Discovery Foundation (ADDF)
This collaboration brings together CTAD’s longstanding leadership and convening power in the Alzheimer’s clinical trials community with the ADDF’s scientific rigor and unique venture philanthropy model. Together, these capabilities enable the identification and elevation of the most promising innovations emerging from the biotech sector.
This year, CTAD is elevating the Biotech Showcase to a next level, reflecting the growing impact of innovation across the biotech landscape is advancing Alzheimer’s research. Hosted in the main ballroom and open to the full CTAD26 audience, these dedicated sessions bring unparalleled visibility to the most promising innovations in Alzheimer's research.
The inaugural Biotech Showcase session will kick-off with a panel of leading Alzheimer’s experts and investors, setting the stage for a thought-provoking and high-impact exchange at intersection of science, clinical development, and investment. This panel offers a unique opportunity for the research community to hear directly from investors and venture capital leaders on emerging trends, what they look for when making investment decisions and how best to attract investors.
Selected biotech companies will then take the floor for dynamic flash presentations, each featuring:
A 3-minute / 3-slide lightning talk to present their science and pipeline.
3 minutes of live Q&A with moderators, expert panelists, and attendees.
Real-time feedback from world-class AD clinical researchers and industry leaders.
Direct exposure to investors and key decision-makers actively engaged in the Alzheimer's space.
High-value networking opportunities with the global AD community.
Participating in the CTAD26 Biotech Showcase is more than a speaking slot — it is a one-of-a-kind opportunity to gain increased for visibility, credibility, and connections that have the potential to transform the trajectory of your program.